Alx Oncology Holdings (ALXO) Revenue (2019 - 2020)
Alx Oncology Holdings (ALXO) posted Revenue of $527000.0 for Q2 2020, down 19.54% sequentially from $655000.0 in Q1 2020, and down 59.31% YoY from $1.3 million in Q3 2019.
Alx Oncology Holdings (ALXO) Revenue (2019 - 2020) Analysis & Trends
Alx Oncology Holdings has reported Revenue for 2 years, with the latest figure at $527000.0 in Q2 2020.
- Quarterly Revenue fell 59.31% year-over-year to $527000.0 in Q2 2020, while the trailing twelve-month figure through Mar 2021 was $527000.0 (down 88.07% YoY) and the FY2020 annual result came in at $1.2 million, down 75.35% from the prior year.
- Revenue slipped to $527000.0 in Q2 2020 per ALXO's latest filing, from $655000.0 in the prior quarter.
- Over five years, Revenue peaked at $1.3 million in Q2 2019 and troughed at $527000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Alx Oncology Holdings | 270.90 Mn | 270.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 527,000.00 |
| Mar 31, 2020 | 655,000.00 |
| Dec 31, 2019 | 1.21 Mn |
| Sep 30, 2019 | 1.26 Mn |
| Jun 30, 2019 | 1.30 Mn |